Key facts
- This page summarizes Robert Azelby's Form 3 filing for ADC Therapeutics SA (ADCT).
- 0 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 02 Jan 2024, 20:06.
Robert Azelby - 02 Jan 2024 Form 3 Insider Report for ADC Therapeutics SA (ADCT)
- Reporting relationship
- Director
- Issuer ticker
- ADCT
- Reported as of
- 02 Jan 2024
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 02 Jan 2024, 20:06:10 UTC
- Prior SEC filing
- 11 Aug 2023
- Next SEC filing
- 01 Mar 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Ameet Mallik, as Attorney-in-Fact for Robert Azelby
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Robert Azelby filed Form 3 for ADC Therapeutics SA (ADCT) on 02 Jan 2024.
Change
- Previous filing in this sequence was filed on 11 Aug 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ADCT
holding
Common Shares
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 20,000
- Date
- 02 Jan 2024
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ADCT
holding
Derivative
Stock Options (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 02 Jan 2024
- Ownership
- Direct
- Underlying class
- Common Shares
- Underlying amount
- 31,000
- Exercise price
- $2.29
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Each restricted share unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Shares. The RSUs were granted on June 14, 2023 and vest 100% as of the date of the Issuer's next scheduled annual meeting of shareholders, subject to the Reporting Person's continued service to the Issuer through the relevant vesting date.
Footnote F2
This option vests over four years from June 14, 2023, with 1/4 vesting on the first anniversary of such date, and the remainder vesting monthly in 36 equal installments, subject to continued service through each such vesting date.
SEC remarks
Exhibit List - Exhibit 24 - Power of Attorney